×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Latera
clinical
4,511 words
KG: rapamycin
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
evidence:strong
Contents
Rapamycin ALS Trial - mTOR Inhibition for Amyotrophic Lateral Sclerosis
Knowledge Graph
Related Hypotheses (30)
APOE-Dependent Autophagy Restoration
Score: 0.61
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.51
Multiplexed Base Editing for Simultaneous Neuroprotective Ge
Score: 0.53
Acid-Degradable LNP-Mediated Prenatal CRISPR Intervention fo
Score: 0.47
TREM2-Dependent Microglial Senescence Transition
Score: 0.69
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.68
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Transcriptional Autophagy-Lysosome Coupling
Score: 0.66
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
Multi-Modal Stress Response Harmonization
Score: 0.60
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.59
Circadian-Synchronized Proteostasis Enhancement
Score: 0.58
PARP1 Inhibition Therapy
Score: 0.58
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.56
Competitive APOE4 Domain Stabilization Peptides
Score: 0.56
Chromatin Accessibility Restoration via BRD4 Modulation
Score: 0.56
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.55
Circadian Clock-Autophagy Synchronization
Score: 0.55
Senescent Cell Mitochondrial DNA Release
Score: 0.54
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.53
Phase-Separated Organelle Targeting
Score: 0.52
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.52
Membrane Cholesterol Gradient Modulators
Score: 0.52
Matrix Stiffness Normalization via Targeted Lysyl Oxidase In
Score: 0.51
Heat Shock Protein 70 Disaggregase Amplification
Score: 0.51
Autophagosome Maturation Checkpoint Control
Score: 0.49
Lysosomal Calcium Channel Modulation Therapy
Score: 0.49
Lysosomal Enzyme Trafficking Correction
Score: 0.49
Show 25 more
Related Analyses (30)
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · failed
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do pathological stress granules in neurodegeneration esc
neurodegeneration · failed
What determines the specificity of TDP-43-induced mitochondr
neurodegeneration · failed
How does chronic cGAS/STING activation downstream of TDP-43
neuroinflammation · failed
What mechanisms drive TDP-43 pathology specifically in Alzhe
neurodegeneration · failed
What mechanisms underlie neuronal resistance to autophagy in
neurodegeneration · failed
What upstream mechanisms cause TDP-43 to trigger mPTP openin
neurodegeneration · failed
What are the neuron-specific effects of ALS-causing mutation
neurodegeneration · failed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
What are the molecular signatures that distinguish protectiv
neurodegeneration · failed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · failed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Show 25 more
Related Experiments (26)
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · proposed · Score: 0.90
Autophagy receptor identification for stress granule elimina
exploratory · proposed · Score: 0.90
Autophagy receptor knockout effects on stress granule accumu
exploratory · proposed · Score: 0.85
Show 21 more
See Also (4)
Aging vs Neurodegeneration: Mechanistic Comparison Matr
mechanism · KG edge: therapeutic_target
Actin Cytoskeleton Dynamics in Neurodegeneration
mechanism · KG edge: co_discussed
AIF1 Gene
gene · KG edge: targets
ACTB Gene
gene · KG edge: activates
Knowledge Graph (12 edges)
rapamycin
inhibits
MTORC1
rapamycin
inhibits
mTOR
rapamycin
treats
seizures
rapamycin
activates
autophagy
rapamycin
treats
stroke
rapamycin
inhibits
MTOR
rapamycin
prevents
aging
rapamycin
activates
PARKIN
rapamycin
targets
RUBCN
rapamycin
targets
ATG